Dr Carraway on the Importance of NGS in Relapsed/Refractory AML
Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.
Source: onclive.com
Immune Oncology Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Immune Oncology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Immune Oncology Program Today - Breaking & Trending Today
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Source: onclive.com
Dr Deng on the Benefits of Pirtobrutinib in CLL
Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.
Source: onclive.com
Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
Source: onclive.com
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Source: onclive.com